Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H ( (HK:1541) ) has shared an update.
ImmuneOnco Biopharmaceuticals has announced that the National Medical Products Administration of China has accepted its application for a clinical trial of IMC-003/IMM72, aimed at treating pulmonary arterial hypertension. This acceptance represents a significant milestone in the company’s efforts to advance clinical research in non-oncology diseases, potentially enhancing its market position and offering new treatment options for stakeholders.
More about ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a biopharmaceutical company based in China, focusing on the development of innovative therapies for non-oncology diseases. The company holds global intellectual property and commercialization rights for its products, including the IMC-003/IMM72 fusion protein.
YTD Price Performance: 35.66%
Average Trading Volume: 7,427,017
Technical Sentiment Signal: Hold
Current Market Cap: HK$2.38B
For an in-depth examination of 1541 stock, go to TipRanks’ Stock Analysis page.